- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ASCO Provides Input on CMMI's
ASCO has been working in parallel with various other institutions to generate a patient-centered oncology payment reform model.
ASCO recently submitted comments to the Centers for Medicare and Medicaid Innovation (CMMI)—a component of the Centers for Medicare & Medicaid Services (CMS)—regarding the center’s proposed cancer care payment and service delivery model, Preliminary Design for an Oncology Focused Model (OCM). ASCO offered specific recommendations for the proposed model and highlighted areas where clarification or refinement may be needed.
The CMMI model relies on adjustments to the current fee for service payment system, attempting to control costs while maintaining quality of care. In its September 18, 2014, letter, ASCO supported the inclusion of OCM among the payment reform models that will be tested to determine new approaches to payment for oncology care; however, ASCO also urged the center to test models that include more fundamental reform that moves away from fee for service—a “change many oncology practices believe is vital to sustaining a robust cancer care delivery system.”
ASCO offered recommendations on several aspects of OCM, such as quality measurement and improvement, risk adjustment, emergency department visits and hospitalizations, clinical trials, and mortality rates as a measure of performance. The society further stressed that in order to be meaningful, the incentives embedded in OCM must come from decisions that are under the control of the oncology practice, that performance measures must be robust and applicable to the patient population, and that the overall system must reflect the variability in labor and resources required to treat patients with cancer.
ASCO's press release: http://bit.ly/1ugOgZA
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Study Highlights Disparities in Access to In-Network Mental Health Care vs Medical Care
April 17th 2024While health plans often employ reimbursement rates as a tool to incentivize provider participation within their networks, study results showed reimbursement rates for office visits with medical/surgical clinicians were on average 22% higher than behavioral health clinicians.
Read More
